BIOLOGICALS, published by Academic Press Ltd - Elsevier Science Ltd, is a prestigious journal dedicated to advancing the fields of applied microbiology, biotechnology, immunology, and pharmacology. With an ISSN of 1045-1056 and E-ISSN of 1095-8320, this journal has established itself as a vital resource for researchers and practitioners, offering rigorous peer-reviewed content that spans converging disciplines from 1990 to 2024. With a commendable presence in the field, it ranks in the Q3 category across multiple domains, including applied microbiology and biotechnology, highlighting its contribution to critical advancements and knowledge dissemination. The journal's rankings reflect its relevance, with notable placements in Scopus Ranks, ensuring it remains an important platform for innovative research and discussion. Although it does not currently offer Open Access, the journal’s comprehensive review process guarantees the quality of published work, making it essential reading for professionals, academics, and students seeking to stay informed about the latest developments in biology and life sciences.

AIMS Allergy and Immunology is a prestigious open access journal dedicated to advancing knowledge in the fields of allergy and immunology. Published by the American Institute of Mathematical Sciences (AIMS), this journal provides a vibrant platform for researchers, practitioners, and scholars to share groundbreaking findings and insights. Recognized for its commitment to disseminating high-quality research since its inception in 2017, AIMS Allergy and Immunology contributes significantly to the understanding of complex immunological mechanisms and allergic responses, thus playing a pivotal role in enhancing clinical practices and therapeutic strategies. With its ISSN 2575-615X, the journal aims to facilitate a robust exchange of ideas and promote collaboration within the scientific community. Researchers and practitioners are encouraged to access the latest studies and reviews, which are all freely available online, ensuring that vital information reaches a global audience without barriers. Together, we can tackle the challenges posed by allergies and immune disorders through rigorous scientific inquiry and innovation.

Medical Microbiology and Immunology is a renowned journal published by Springer, serving as a pivotal resource in the fields of microbiology and immunology. Established in 1971 and continuing its legacy through 2024, this journal features cutting-edge research and reviews that address critical advancements and challenges within these dynamic fields. With an impressive impact factor and a robust ranking, including Q1 categories in both Microbiology (medical) and Immunology, it stands at the forefront of scholarly communication, ranking 21st out of 140 in the realm of Medical Microbiology. Researchers and professionals are encouraged to explore a variety of studies that delve into the interactions between microorganisms and the immune system, making it an essential resource for anyone fascinated by these interconnected realms of health sciences. Although not open access, the journal is widely accessible through institutional libraries, ensuring that significant findings reach a global audience. The University of New York Plaza serves as its operational hub in the USA, reinforcing its international influence and dedication to advancing knowledge in microbiology and immunology.

Influenza and Other Respiratory Viruses, published by WILEY, serves as a prominent peer-reviewed platform for the dissemination of research contributing to the understanding and management of respiratory viral infections. With an impressive impact factor and established as an Open Access journal since 2014, it ensures maximum visibility and accessibility of pivotal research findings in the realm of Epidemiology, Infectious Diseases, Public Health, and Pulmonary and Respiratory Medicine. Registered under the ISSN 1750-2640 and E-ISSN 1750-2659, the journal boasts Q1 rankings in four critical categories as of 2023, underscoring its significance within the scientific community. Researchers, professionals, and students can benefit from the convergence of knowledge that this journal facilitates from 2007 to 2024, fostering advancements in understanding viral pathogens and innovative treatment strategies that are increasingly vital to public health efforts globally.

Eurosurveillance is a prestigious journal dedicated to the field of epidemiology, public health, and infectious diseases, published by the European Centre for Disease Prevention and Control since 1996. With an impressive Q1 ranking across various categories, including Epidemiology and Public Health, it consistently stands at the forefront of research dissemination, making it an invaluable resource for researchers, professionals, and students alike. The journal boasts an outstanding reputation, as evidenced by its Scopus rankings, where it ranks in the top 1% to 3% in multiple relevant categories. As an Open Access publication, Eurosurveillance ensures that vital findings are freely accessible to a global audience, fostering collaboration and innovation in the fight against infectious diseases. With a dedicated reach from 2001 to 2024, the journal addresses contemporary challenges in public health and virology, reinforcing its significance in shaping policies and research initiatives across the world.

EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE is a prominent scholarly journal published by CESKA LEKARSKA SPOLECNOST J EV PURKYNE in the Czech Republic. With an ISSN of 1210-7913, this journal has been at the forefront of research since its inception in 1994, showcasing a rich repository of studies bridging the domains of epidemiology, microbiology, immunology, and infectious diseases, and reflecting advancements over three decades. Although it currently falls within the Q4 category in multiple fields including Epidemiology and Microbiology, the journal serves an essential role in disseminating knowledge and fostering discussions around public health challenges. The contributions made through its pages are vital for researchers, healthcare professionals, and students aiming to enhance their understanding of complex biomedical issues. While it does not offer open access, the journal remains a critical resource in its niches, inviting readers to engage with the latest findings and methodologies reshaping the landscape of health science.

The Japanese Journal of Infectious Diseases, published by the National Institute of Infectious Diseases in Japan, serves as a vital platform for researchers, clinicians, and public health professionals committed to advancing the field of infectious disease science. With an ISSN of 1344-6304 and an E-ISSN of 1884-2836, this journal has maintained its academic rigor since its inception in 1961 and continues to contribute significantly to the global understanding of infectious diseases. The journal holds a Q3 ranking in the categories of Infectious Diseases, Miscellaneous Medicine, and Medical Microbiology as of 2023, reflecting its important role in disseminating impactful research. With many articles available through Open Access, it ensures wide accessibility to the latest discoveries and insights. Researchers can expect to find high-quality studies that address critical challenges in the control and prevention of infectious diseases, making this journal an essential resource for anyone engaging in this critical field.

Vaccine: X, published by Elsevier, is a premier open access journal dedicated to advancing research in the interdisciplinary fields of immunology and microbiology, infectious diseases, molecular medicine, and public health. With an ISSN of 2590-1362 and operating since 2019, the journal has rapidly established an influential role, achieving Q2 rankings in major categories such as Immunology and Microbiology, Infectious Diseases, and Public Health for 2023. Its commitment to disseminating cutting-edge research is evident from its broad scope, focusing on innovative vaccines and therapies that are critical for global health. Researchers and professionals will find value in the accessible nature of the journal, which has been recognized for its contributions to veterinary medicine as well, with a Q1 ranking in the miscellaneous veterinary category. The journal proudly showcases high-quality, peer-reviewed articles and welcomes submissions that push the boundaries of current knowledge, making it an essential resource for anyone involved in vaccine research and development.

Biosafety and Health is a leading peer-reviewed journal published by ELSEVIER, dedicated to advancing knowledge and practice in the fields of biotechnology, infectious diseases, microbiology, and public health. With an ISSN of 2096-6962 and an E-ISSN of 2590-0536, this Open Access journal has been accessible to the global research community since 2019, fostering collaboration and innovation from its base in the Netherlands. Ranked Q2 in multiple categories according to the latest metrics, including Biotechnology and Microbiology (medical), it stands as a testament to high-quality, impactful research that influences clinical and environmental practices. The journal has achieved substantial recognition in various medical fields, ranking in the 88th percentile for Public Health, Environmental and Occupational Health, and the 78th percentile for Infectious Diseases. Researchers and practitioners seeking to contribute to this evolving domain are encouraged to submit their findings, as the journal aims to promote interdisciplinary dialogue and address pressing global health challenges.

Infectious Agents and Cancer is a pivotal open access journal published by BMC, dedicated to advancing research at the intersection of infectious diseases and oncology. Since its inception in 2006, this journal has provided a platform for the exploration of the complex relationships between infectious agents and cancer development, aimed at researchers, healthcare professionals, and students alike. With a broad scope encompassing epidemiology and cancer research, the journal holds an impressive ranking in the Q3 quadrant for epidemiology, infectious diseases, and oncology in 2023, while also featuring in the Q4 category for cancer research. This distinguished journal not only contributes to the enrichment of scientific knowledge but also fosters collaborative efforts towards innovative solutions in the fight against cancer. Being part of the UK publishing landscape, the journal is accessible to a global audience, ensuring that vital research findings are disseminated widely to inform policy and practice in health sciences.